NASDAQ:DOVA - Dova Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$30.00 -0.35 (-1.15 %)
(As of 06/19/2018 02:13 PM ET)
Previous Close$30.42
Today's Range$29.50 - $30.52
52-Week Range$16.98 - $37.00
Volume4,551 shs
Average Volume416,566 shs
Market Capitalization$854.48 million
P/E Ratio-21.73
Dividend YieldN/A
Dova Pharmaceuticals logoDova Pharmaceuticals, Inc., a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead drug candidate is avatrombopag that has completed Phase III clinical trials for the treatment of thrombocytopenia in patients with chronic liver disease. Dova Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Durham, North Carolina.

Receive DOVA News and Ratings via Email

Sign-up to receive the latest news and ratings for DOVA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations


Debt-to-Equity RatioN/A
Current Ratio35.32
Quick Ratio35.32


Trailing P/E Ratio-21.73
Forward P/E Ratio-13.76
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$2.38 per share
Price / Book12.61


EPS (Most Recent Fiscal Year)($1.40)
Net Income$-29,950,000.00
Net MarginsN/A
Return on Equity-61.19%
Return on Assets-43.40%


Outstanding Shares28,190,000

Dova Pharmaceuticals (NASDAQ:DOVA) Frequently Asked Questions

What is Dova Pharmaceuticals' stock symbol?

Dova Pharmaceuticals trades on the NASDAQ under the ticker symbol "DOVA."

How were Dova Pharmaceuticals' earnings last quarter?

Dova Pharmaceuticals Inc (NASDAQ:DOVA) released its quarterly earnings results on Wednesday, May, 9th. The company reported ($0.52) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.47) by $0.05. View Dova Pharmaceuticals' Earnings History.

What price target have analysts set for DOVA?

4 brokers have issued 1-year target prices for Dova Pharmaceuticals' stock. Their forecasts range from $29.00 to $35.00. On average, they anticipate Dova Pharmaceuticals' share price to reach $32.25 in the next twelve months. View Analyst Ratings for Dova Pharmaceuticals.

Who are some of Dova Pharmaceuticals' key competitors?

Who are Dova Pharmaceuticals' key executives?

Dova Pharmaceuticals' management team includes the folowing people:
  • Mr. Alexander C. Sapir, Pres, CEO & Director (Age 51)
  • Dr. Lee F. Allen, Chief Medical Officer (Age 66)
  • Mr. Mark W. Hahn, Chief Financial Officer (Age 55)
  • Mr. Kevin Laliberte, Sr. VP of Product Devel. (Age 40)

When did Dova Pharmaceuticals IPO?

(DOVA) raised $66 million in an initial public offering on Thursday, June 29th 2017. The company issued 4,100,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Jefferies and Leerink Partners acted as the underwriters for the IPO.

Has Dova Pharmaceuticals been receiving favorable news coverage?

Headlines about DOVA stock have been trending somewhat positive on Tuesday, according to Accern Sentiment. The research firm ranks the sentiment of media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Dova Pharmaceuticals earned a news impact score of 0.09 on Accern's scale. They also assigned news articles about the company an impact score of 46.07 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

Who are Dova Pharmaceuticals' major shareholders?

Dova Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include PERCEPTIVE ADVISORS LLC (10.30%), BlackRock Inc. (2.30%), Nexthera Capital LP (2.02%), Wells Fargo & Company MN (1.20%), Pier Capital LLC (0.77%) and GW&K Investment Management LLC (0.51%). Company insiders that own Dova Pharmaceuticals stock include Alex Sapir, Kevin Laliberte, Lee F Md Phd Allen, Life Sciences Maste Perceptive, Paul B Manning and Steven M Goldman. View Institutional Ownership Trends for Dova Pharmaceuticals.

Which major investors are buying Dova Pharmaceuticals stock?

DOVA stock was bought by a variety of institutional investors in the last quarter, including GW&K Investment Management LLC, venBio Select Advisor LLC, Nexthera Capital LP, Candriam Luxembourg S.C.A., BlackRock Inc., Citigroup Inc., Pier Capital LLC and Wells Fargo & Company MN. Company insiders that have bought Dova Pharmaceuticals stock in the last two years include Alex Sapir, Kevin Laliberte, Lee F Md Phd Allen, Life Sciences Maste Perceptive, Paul B Manning and Steven M Goldman. View Insider Buying and Selling for Dova Pharmaceuticals.

How do I buy shares of Dova Pharmaceuticals?

Shares of DOVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Dova Pharmaceuticals' stock price today?

One share of DOVA stock can currently be purchased for approximately $30.21.

How big of a company is Dova Pharmaceuticals?

Dova Pharmaceuticals has a market capitalization of $854.48 million. The company earns $-29,950,000.00 in net income (profit) each year or ($1.40) on an earnings per share basis. Dova Pharmaceuticals employs 33 workers across the globe.

How can I contact Dova Pharmaceuticals?

Dova Pharmaceuticals' mailing address is 240 Leigh Farm Road Suite 245, Durham NC, 27707. The company can be reached via phone at 919-748-5975 or via email at [email protected]

MarketBeat Community Rating for Dova Pharmaceuticals (DOVA)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  88 (Vote Outperform)
Underperform Votes:  97 (Vote Underperform)
Total Votes:  185
MarketBeat's community ratings are surveys of what our community members think about Dova Pharmaceuticals and other stocks. Vote "Outperform" if you believe DOVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DOVA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/19/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.